AstraZeneca

News

AZ and CRUK team up to go all-in on CRISPR

AstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling and big data processing that will develop CRISPR technology to b

News

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication

News

AstraZeneca searching for Pascal Soriot successor - report

AstraZeneca is looking for a successor to CEO Pascal Soriot just in case he decides to move on, according to a press report.

News

AstraZeneca's immunotherapy fails in key lung cancer trial

AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck

Digital

The future of pharma in a digital world

How is digital health impacting pharma? An exclusive live broadcast from Frontiers Health 2018 addressed this subject on 15 November.

Views & Analysis

AstraZeneca may have hit rock bottom, but can it rise to new...

Back in 2014, Pascal Soriot CEO of AstraZeneca managed to stave off a takeover bid from Pfizer with a bold promise to return the company to growth and achieve revenues of between $41 to $42 billion

AZ and CRUK team up to go all-in on CRISPR

AZ's cancer drug fails again, Roche's rival gets new use

AstraZeneca searching for Pascal Soriot successor - report

AstraZeneca's immunotherapy fails in key lung cancer trial

The future of pharma in a digital world

AstraZeneca may have hit rock bottom, but can it rise to new...

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks